US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
WO1988007089A1
(fr)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Anticorps alteres
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
EP1136556B1
(fr)
|
1991-11-25 |
2005-06-08 |
Enzon, Inc. |
Procédé pour produire de protéines multivalents de fixation de l'antigène
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
PT859841E
(pt)
|
1995-08-18 |
2002-11-29 |
Morphosys Ag |
Bibliotecas de proteinas/ (poli) peptidos
|
DE19629378A1
(de)
|
1996-07-20 |
1998-01-29 |
Boehringer Ingelheim Kg |
Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE69820866T2
(de)
|
1997-03-24 |
2004-12-30 |
Kyowa Hakko Kogyo Co., Ltd. |
[1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
|
JP4516690B2
(ja)
|
1998-08-11 |
2010-08-04 |
ノバルティス アーゲー |
血管形成阻害活性を有するイソキノリン誘導体
|
KR20010087361A
(ko)
|
1998-09-22 |
2001-09-15 |
히라타 다다시 |
[1,2,4]트리아졸로[1,5-c]피리미딘 유도체
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
EP1637160A3
(fr)
|
1999-05-07 |
2006-05-03 |
Genentech, Inc. |
Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes B
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
IL148021A0
(en)
|
1999-08-23 |
2002-09-12 |
Dana Farber Cancer Inst Inc |
Novel b7-4 molecules and uses therefor
|
US6355653B1
(en)
|
1999-09-06 |
2002-03-12 |
Hoffmann-La Roche Inc. |
Amino-triazolopyridine derivatives
|
CA2392477A1
(fr)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
Nouvelle molecule immunoregulatrice b7-h1,
|
US6803192B1
(en)
|
1999-11-30 |
2004-10-12 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
CN1437478A
(zh)
|
2000-04-25 |
2003-08-20 |
Idec药物公司 |
瑞图希单抗的鞘内施用,用于中枢神经***淋巴瘤的治疗
|
DK1283839T3
(da)
|
2000-05-26 |
2005-07-25 |
Schering Corp |
Adenosin A2a-receptorantagonister
|
IL153231A0
(en)
|
2000-06-28 |
2003-07-06 |
Smithkline Beecham Plc |
Wet milling process
|
CN101555283B
(zh)
|
2001-01-17 |
2012-03-21 |
生物权威国际有限公司 |
针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
EP1406611A2
(fr)
|
2001-05-30 |
2004-04-14 |
Alteon, Inc. |
Methode de traitement de maladies fibreuses ou d'autres indications
|
WO2002096318A2
(fr)
|
2001-05-30 |
2002-12-05 |
Alteon, Inc. |
Methode de traitement du glaucome
|
BR0212760A
(pt)
|
2001-09-19 |
2004-12-07 |
Aventis Pharma Sa |
Compostos quìmicos
|
JPWO2003028732A1
(ja)
|
2001-09-28 |
2005-01-13 |
協和醗酵工業株式会社 |
受容体拮抗剤
|
WO2003031587A2
(fr)
|
2001-10-09 |
2003-04-17 |
The Regents Of The University Of California |
Utilisation d'inhibiteurs de stat-6 comme agents therapeutiques
|
ATE335490T1
(de)
|
2001-10-30 |
2006-09-15 |
Novartis Pharma Gmbh |
Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung
|
CA2466279A1
(fr)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
AR038366A1
(es)
|
2001-11-30 |
2005-01-12 |
Schering Corp |
Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
|
PL220952B1
(pl)
|
2002-01-22 |
2016-01-29 |
Warner Lambert Co |
2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
|
JPWO2003068776A1
(ja)
|
2002-02-15 |
2005-06-02 |
協和醗酵工業株式会社 |
[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
JPWO2004029056A1
(ja)
|
2002-09-24 |
2006-01-26 |
協和醗酵工業株式会社 |
[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
|
TWI335913B
(en)
|
2002-11-15 |
2011-01-11 |
Vertex Pharma |
Diaminotriazoles useful as inhibitors of protein kinases
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
ATE514713T1
(de)
|
2002-12-23 |
2011-07-15 |
Wyeth Llc |
Antikörper gegen pd-1 und ihre verwendung
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
WO2004065416A2
(fr)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Banques de phages anticorps synthetiques
|
US20050008625A1
(en)
|
2003-02-13 |
2005-01-13 |
Kalobios, Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO2004079013A1
(fr)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) utilisee dans le diagnostic et le traitement du cancer du pancreas
|
RU2366655C2
(ru)
|
2003-03-14 |
2009-09-10 |
Оно Фармасьютикал Ко., Лтд. |
Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
AR043633A1
(es)
|
2003-03-20 |
2005-08-03 |
Schering Corp |
Ligandos de receptores de canabinoides
|
PL1613350T3
(pl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
|
WO2004092172A2
(fr)
|
2003-04-09 |
2004-10-28 |
Biogen Idec Ma Inc. |
Triazolo[1,5-c]pyrimidines et pyrazolo[1,5-c]pyrimidines et procedes de preparation et d'utilisation de celles-ci
|
DE602004018637D1
(de)
|
2003-04-09 |
2009-02-05 |
Biogen Idec Inc |
A2a-adenosinrezeptorantagonisten
|
EP1615931A1
(fr)
|
2003-04-09 |
2006-01-18 |
Biogen Idec MA Inc. |
Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
|
KR20060037252A
(ko)
|
2003-06-10 |
2006-05-03 |
교와 핫꼬 고교 가부시끼가이샤 |
불안 장애의 치료 방법
|
JP4667383B2
(ja)
|
2003-06-13 |
2011-04-13 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
アグリコシル抗cd154(cd40リガンド)抗体およびその使用
|
EP1656353B1
(fr)
|
2003-08-14 |
2010-01-27 |
F. Hoffmann-La Roche Ag |
Modulateurs gabanergiques
|
NZ545776A
(en)
|
2003-08-22 |
2009-05-31 |
Biogen Idec Inc |
Improved antibodies having altered effector function and methods for making the same
|
WO2005020921A2
(fr)
|
2003-08-29 |
2005-03-10 |
Exelixis, Inc. |
Modulateurs c-kit et leurs procedes d'utilisation
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
GB0403819D0
(en)
|
2004-02-20 |
2004-03-24 |
Merck Sharp & Dohme |
New compounds
|
ATE438400T1
(de)
|
2004-03-19 |
2009-08-15 |
Warner Lambert Co |
Imidazopyridin- und imidazopyrimidin-derivate als antibakterielle mittel
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
WO2005118555A1
(fr)
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
ES2396135T3
(es)
|
2004-06-10 |
2013-02-19 |
Irm Llc |
Compuestos y composiciones como inhibidores de proteínas cinasas
|
AU2005256963A1
(en)
|
2004-06-23 |
2006-01-05 |
Centre National De La Recherche Scientifique |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
WO2006004702A1
(fr)
|
2004-06-25 |
2006-01-12 |
Amgen Inc. |
Triazols et indazols condenses convenant pour le traitement de maladies induites par les citokines et autres pathologies
|
EP1828946B1
(fr)
|
2004-10-15 |
2018-02-28 |
Symantec International |
Mot de passe a usage unique
|
WO2006044687A2
(fr)
|
2004-10-15 |
2006-04-27 |
Takeda San Diego, Inc. |
Inhibiteurs de kinase
|
US20060211739A1
(en)
|
2005-02-08 |
2006-09-21 |
Arturo Perez-Medrano |
Use of selective P2X7 receptor antagonists
|
EP2161336B2
(fr)
|
2005-05-09 |
2017-03-29 |
ONO Pharmaceutical Co., Ltd. |
Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
|
AU2006247064A1
(en)
|
2005-05-18 |
2006-11-23 |
Biogen Idec Inc. |
Methods for treating fibrotic conditions
|
JPWO2006129626A1
(ja)
|
2005-05-30 |
2009-01-08 |
協和醗酵工業株式会社 |
[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体の製造法
|
ATE556712T1
(de)
|
2005-06-07 |
2012-05-15 |
Kyowa Hakko Kirin Co Ltd |
A2a antagonisten zur behandlung von motorischen störungen
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
JP4986451B2
(ja)
|
2005-06-30 |
2012-07-25 |
信一郎 礒部 |
マーキング剤
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
WO2007011759A2
(fr)
|
2005-07-15 |
2007-01-25 |
Kalypsys, Inc. |
Inhibiteurs de la kinesine mitotique
|
US7709468B2
(en)
|
2005-09-02 |
2010-05-04 |
Abbott Laboratories |
Imidazo based heterocycles
|
CA2628455A1
(fr)
|
2005-11-10 |
2007-05-24 |
Schering Corporation |
Imidazopyrazines inhibant la proteine kinase
|
CN102936250B
(zh)
|
2005-11-17 |
2014-07-09 |
Osi医药有限责任公司 |
稠合双环mTOR抑制剂
|
BRPI0620463A2
(pt)
|
2005-12-22 |
2011-11-16 |
Alcon Res Ltd |
composição farmacêutica oftálmica, compostos, e seus usos
|
EP2010505B1
(fr)
|
2006-03-28 |
2012-12-05 |
Atir Holding S.A. |
Composés hétérocycliques et leurs utilisations dans le traitement de troubles sexuels
|
US8008332B2
(en)
|
2006-05-31 |
2011-08-30 |
Takeda San Diego, Inc. |
Substituted indazoles as glucokinase activators
|
EA200870592A1
(ru)
|
2006-05-31 |
2009-08-28 |
Галапагос Н.В. |
Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
|
EP2037905B1
(fr)
|
2006-06-23 |
2013-05-01 |
Radius Health, Inc. |
Traitement de symptômes vasomoteurs par des modulateurs des récepteurs d' strogène sélectifs
|
MX2009000170A
(es)
|
2006-06-23 |
2009-01-23 |
Incyte Corp |
Derivados de purinona como agonistas de hm74a.
|
EP2078732B1
(fr)
|
2006-07-10 |
2015-09-16 |
Fujita Health University |
Procédé pour l'identification des anticorps diagnostic ou thérapeutiques par cytométrie en flux
|
EP1889846A1
(fr)
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Dérivés de purine comme agonistes du recepteur A2a
|
US20080021026A1
(en)
|
2006-07-20 |
2008-01-24 |
Mehmet Kahraman |
Benzothiophene inhibitors of rho kinase
|
DE102006041292A1
(de)
|
2006-09-01 |
2008-03-06 |
Henkel Kgaa |
Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
|
WO2008037607A1
(fr)
|
2006-09-25 |
2008-04-03 |
Basf Se |
Composés hétérocycliques à teneur en groupe carbonyle et leur utilisation pour lutter contre des champignons phytopathogènes
|
WO2008056176A1
(fr)
|
2006-11-10 |
2008-05-15 |
Scottish Biomedical Limited |
Pyrazolopyrimidines utiles comme inhibiteurs de la phosphodiestérase
|
KR20090127867A
(ko)
|
2006-12-05 |
2009-12-14 |
네이셔널 치아오 텅 유니버시티 |
인다졸 화합물
|
DE102007012645A1
(de)
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
NZ580394A
(en)
|
2007-04-10 |
2011-10-28 |
Lundbeck & Co As H |
Heteroaryl amide analogues as p2x7 antagonists
|
US8039505B2
(en)
|
2007-04-11 |
2011-10-18 |
University Of Utah Research Foundation |
Compounds for modulating T-cells
|
US8133895B2
(en)
|
2007-05-10 |
2012-03-13 |
Janssen Pharmaceutica N.V. |
Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
|
CN101855222A
(zh)
|
2007-05-10 |
2010-10-06 |
通用电气健康护理有限公司 |
对***素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
|
HUP0700395A2
(en)
|
2007-06-07 |
2009-03-02 |
Sanofi Aventis |
Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
|
CN102131828B
(zh)
|
2007-06-18 |
2015-06-17 |
默沙东有限责任公司 |
针对人程序性死亡受体pd-1的抗体
|
MX2010000716A
(es)
|
2007-07-18 |
2010-03-26 |
Novartis Ag |
Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
EA201000201A1
(ru)
|
2007-08-10 |
2010-12-30 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
|
US8062852B2
(en)
|
2007-10-01 |
2011-11-22 |
The Children's Hospital And Regional Medical Center |
Detection and treatment of autoimmune disorders
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
US20100261679A1
(en)
|
2007-10-18 |
2010-10-14 |
James Sutton |
CSF-1R, Inhibitors, Compositions, and Methods of Use
|
US20090118301A1
(en)
|
2007-11-02 |
2009-05-07 |
Arbor Vita Corporation |
Compositions and Methods for Treating Cancer
|
US20100292232A1
(en)
|
2007-11-09 |
2010-11-18 |
Daniel Elleder |
Non-nucleoside reverse transcriptase inhibitors
|
PE20091074A1
(es)
|
2007-12-13 |
2009-07-26 |
Bayer Healthcare Ag |
Triazolotriazinas y triazolopirazinas y su uso
|
EP2231656A1
(fr)
|
2007-12-19 |
2010-09-29 |
Amgen Inc. |
Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
|
CA2710194C
(fr)
|
2007-12-19 |
2014-04-22 |
Amgen Inc. |
Inhibiteurs de la p13 kinase
|
US8222259B2
(en)
|
2008-03-04 |
2012-07-17 |
Schering Corporation |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
EP2252293B1
(fr)
|
2008-03-14 |
2018-06-27 |
Intellikine, LLC |
Inhibiteurs de kinases, et procédés d utilisation associés
|
WO2009117421A2
(fr)
|
2008-03-17 |
2009-09-24 |
Kalypsys, Inc. |
Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
|
JP5620365B2
(ja)
|
2008-03-21 |
2014-11-05 |
エンソン インコーポレイテッド |
多官能分子システムを用いた積層体への金属の接着促進
|
US20090281089A1
(en)
|
2008-04-11 |
2009-11-12 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
EP2444403A1
(fr)
|
2008-04-18 |
2012-04-25 |
Shionogi Co., Ltd. |
Composé hétérocyclique doté d'une activité inhibitrice sur PI3K
|
TWI473614B
(zh)
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
WO2010010908A1
(fr)
|
2008-07-23 |
2010-01-28 |
協和発酵キリン株式会社 |
Agent thérapeutique antimigraineux
|
WO2010033906A2
(fr)
|
2008-09-19 |
2010-03-25 |
President And Fellows Of Harvard College |
Induction efficace de cellules souches pluripotentes au moyen de composés à petite molécule
|
EP2345328A4
(fr)
|
2008-09-19 |
2014-06-25 |
Sumitomo Chemical Co |
Composition utilisée en milieu agricole
|
WO2010036959A2
(fr)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
|
KR20210060670A
(ko)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
ES2567047T3
(es)
|
2008-12-23 |
2016-04-19 |
Abbvie Inc. |
Derivados de pirimidina anti-virales
|
JP2012513410A
(ja)
|
2008-12-23 |
2012-06-14 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
EP2210891A1
(fr)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
WO2010104306A2
(fr)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
|
US8846673B2
(en)
*
|
2009-08-11 |
2014-09-30 |
Bristol-Myers Squibb Company |
Azaindazoles as kinase inhibitors and use thereof
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
US20110105541A1
(en)
|
2009-10-29 |
2011-05-05 |
Jackson Paul F |
ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
|
US8435994B2
(en)
|
2009-11-16 |
2013-05-07 |
Merck Sharp & Dohme Corp. |
Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
WO2011078143A1
(fr)
|
2009-12-22 |
2011-06-30 |
塩野義製薬株式会社 |
Dérivés de pyrimidine et composition pharmaceutique les contenant
|
WO2011082400A2
(fr)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
|
EP2347769A1
(fr)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Marqueurs de cellules souches de cancer et utilisations associées
|
US20110190269A1
(en)
|
2010-02-01 |
2011-08-04 |
Karlheinz Baumann |
Gamma secretase modulators
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
TW201200518A
(en)
|
2010-03-10 |
2012-01-01 |
Kalypsys Inc |
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
KR101732212B1
(ko)
|
2010-03-18 |
2017-05-02 |
재단법인 한국파스퇴르연구소 |
항감염성 화합물
|
UY33304A
(es)
|
2010-04-02 |
2011-10-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
GB201007187D0
(en)
|
2010-04-29 |
2010-06-09 |
Iti Scotland Ltd |
Ubiquitination modulators
|
WO2011153588A1
(fr)
|
2010-06-10 |
2011-12-15 |
Biota Scientific Management Pty Ltd |
Inhibiteurs de polymérase virale
|
US20120083498A1
(en)
|
2010-06-17 |
2012-04-05 |
Fatah Kashanchi |
Modulators of Viral Transcription, and Methods and Compositions Therewith
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
AU2011295440B2
(en)
|
2010-08-27 |
2015-06-11 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
SG10201508715YA
(en)
|
2010-10-25 |
2015-11-27 |
G1 Therapeutics Inc |
Cdk inhibitors
|
EP2651404B1
(fr)
|
2010-12-14 |
2015-10-14 |
Electrophoretics Limited |
Inhibiteurs de caséine kinase 1 delta (ck1delta)
|
ES2627788T3
(es)
|
2011-01-11 |
2017-07-31 |
Sunovion Pharmaceuticals Inc. |
Compuestos heteroarilo y procedimientos de uso de los mismos
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
AU2012230896B9
(en)
|
2011-03-23 |
2015-06-18 |
Amgen Inc. |
Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
|
KR20140093610A
(ko)
|
2011-04-21 |
2014-07-28 |
재단법인 한국파스퇴르연구소 |
소염 화합물
|
WO2012147890A1
(fr)
|
2011-04-27 |
2012-11-01 |
持田製薬株式会社 |
Nouveau dérivé d'azole
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
EP2604265A1
(fr)
|
2011-12-17 |
2013-06-19 |
Royal College of Surgeons in Ireland (RCSI) |
Antagonistes P2x7 en tant que traitement auxiliaire ou principal contre l'état de mal épileptique
|
WO2013106254A1
(fr)
|
2012-01-11 |
2013-07-18 |
Dow Agrosciences Llc |
Compositions pesticides et procédés qui leur sont associés
|
EA201492069A1
(ru)
|
2012-05-30 |
2015-03-31 |
Ф.Хоффманн-Ля Рош Аг |
Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
|
EP2865671B1
(fr)
|
2012-06-22 |
2017-11-01 |
Sumitomo Chemical Company, Ltd |
Composé hétérocyclique fusionné
|
BR112015001769A2
(pt)
|
2012-07-27 |
2017-08-22 |
Bial Portela & Ca Sa |
Processo para a síntese de compostos de ureia substituída
|
CA2890897A1
(fr)
|
2012-11-14 |
2014-05-22 |
The Board Of Regents Of The University Of Texas System |
Inhibition de l'heterodimerisation de hif-2a avec hif1.beta. (arnt)
|
WO2014126580A1
(fr)
|
2013-02-15 |
2014-08-21 |
Dow Agrosciences Llc |
Compositions pesticides et processus associés à celles-ci
|
ES2705247T3
(es)
|
2013-03-14 |
2019-03-22 |
Univ Columbia |
4-fenilpiperidinas, su preparación y uso
|
US9090697B2
(en)
|
2013-03-15 |
2015-07-28 |
Bayer Healthcare Llc |
Methods for treating bleeding disorders
|
WO2014153424A1
(fr)
|
2013-03-19 |
2014-09-25 |
La Jolla Institute For Allergy And Immunology |
Réduction de diabète chez des patients recevant des inhibiteurs de l'hmg-coa réductase (statines)
|
RU2016105108A
(ru)
|
2013-07-25 |
2017-08-30 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ингибиторы факторов транскрипции и их применение
|
WO2015157955A1
(fr)
|
2014-04-17 |
2015-10-22 |
Abbvie Inc. |
Inhibiteurs de tyrosine kinase de bruton (btk) hétérocyclique
|
US9695167B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
|
MY188940A
(en)
|
2014-07-11 |
2022-01-13 |
Ventana Med Syst Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
JP2017531037A
(ja)
|
2014-10-06 |
2017-10-19 |
フラットレー ディスカバリー ラブ,エルエルシー |
トリアゾロピリジン化合物および嚢胞性線維症の治療のための方法
|
US10766966B2
(en)
|
2014-10-10 |
2020-09-08 |
Innate Pharma |
CD73 blockade
|
US20180030144A1
(en)
|
2014-10-10 |
2018-02-01 |
Innate Pharma |
Cd73 blockade
|
MY191423A
(en)
|
2014-11-10 |
2022-06-27 |
Medimmune Ltd |
Binding molecules specific for cd73 and uses thereof
|
US20160129108A1
(en)
|
2014-11-11 |
2016-05-12 |
Medimmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
|
SI3221363T1
(sl)
|
2014-11-21 |
2020-09-30 |
Bristol-Myers Squibb Company |
Protitelesa proti CD73 in njihova uporaba
|
MA41090A
(fr)
|
2014-12-03 |
2017-10-10 |
H Lundbeck As |
Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
|
EP3257853B1
(fr)
|
2015-02-12 |
2021-11-10 |
Nissan Chemical Corporation |
Composé hétérocyclique condensé et agent de lutte contre des organismes nuisibles
|
ES2751669T3
(es)
*
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
JP6697809B2
(ja)
|
2015-03-06 |
2020-05-27 |
ファーマケア,インク. |
フッ素化リシルオキシダーゼ様2阻害剤とその使用
|
AU2016243939B2
(en)
|
2015-04-03 |
2020-09-03 |
Incyte Holdings Corporation |
Heterocyclic compounds as LSD1 inhibitors
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
MA52119A
(fr)
|
2015-10-19 |
2018-08-29 |
Ncyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
EP3377488B1
(fr)
|
2015-11-19 |
2022-08-10 |
Incyte Corporation |
Composés hétérocycliques utilisés comme immunomodulateurs
|
MX2018006973A
(es)
|
2015-12-09 |
2019-05-16 |
Corvus Pharmaceuticals Inc |
Anticuerpos anti-cd73 humanizados.
|
ES2916874T3
(es)
|
2015-12-17 |
2022-07-06 |
Incyte Corp |
Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
|
MD3394033T2
(ro)
|
2015-12-22 |
2021-04-30 |
Incyte Corp |
Compuși heterociclici ca imunomodulatori
|
WO2017112917A1
(fr)
|
2015-12-24 |
2017-06-29 |
Corvus Pharmaceuticals, Inc. |
Méthodes de traitement du cancer
|
CN109071546B
(zh)
|
2016-02-24 |
2021-03-02 |
辉瑞大药厂 |
作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
|
IL295230A
(en)
|
2016-03-04 |
2022-10-01 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
EP4219449A3
(fr)
|
2016-03-16 |
2023-10-11 |
Kura Oncology, Inc. |
Dérivés indoliques substitués et leurs procédés de préparation
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
MA45116A
(fr)
|
2016-05-26 |
2021-06-02 |
Incyte Corp |
Composés hétérocycliques comme immunomodulateurs
|
JP7000357B2
(ja)
|
2016-06-20 |
2022-01-19 |
インサイト・コーポレイション |
免疫調節剤としての複素環化合物
|
TW201803871A
(zh)
|
2016-06-24 |
2018-02-01 |
英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
WO2018004478A1
(fr)
|
2016-06-29 |
2018-01-04 |
Hayat Kimya San. A. Ş. |
Procédé amélioré de production de tissu non tissé mou
|
WO2018013611A1
(fr)
|
2016-07-11 |
2018-01-18 |
Corvus Pharmaceuticals, Inc. |
Anticorps anti-cd73
|
WO2018013789A1
(fr)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Composés hétérocycliques utilisés comme immunomodulateurs
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
EP3872080B1
(fr)
|
2016-09-02 |
2023-08-16 |
Cyclerion Therapeutics, Inc. |
Stimulateurs sgc bicycliques fusionnés
|
BR112019011988A2
(pt)
|
2016-12-13 |
2019-11-05 |
Astellas Pharma Inc |
anticorpo anti-cd73 humana
|
MA56480B1
(fr)
|
2016-12-16 |
2022-12-30 |
Pfizer |
Agonistes du récepteur glp-1 et leurs utilisations
|
WO2018119221A1
(fr)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Dérivés pyridine utilisés en tant qu'immunomodulateurs
|
MD3558990T2
(ro)
|
2016-12-22 |
2023-02-28 |
Incyte Corp |
Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
|
JP7101678B2
(ja)
|
2016-12-22 |
2022-07-15 |
インサイト・コーポレイション |
免疫調節剤としての複素環式化合物
|
WO2018119236A1
(fr)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
|
JP7303108B2
(ja)
|
2016-12-22 |
2023-07-04 |
インサイト・コーポレイション |
免疫調節剤としての二環式複素芳香環化合物
|
US20180177784A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
TWI820013B
(zh)
|
2017-01-23 |
2023-11-01 |
美商銳新醫藥公司 |
作為別構shp2抑制劑之雙環化合物
|
KR20180093088A
(ko)
|
2017-01-24 |
2018-08-20 |
아이-맵 |
항-cd73 항체 및 이것의 사용
|
CN108467386B
(zh)
*
|
2017-02-23 |
2020-11-17 |
江苏恒瑞医药股份有限公司 |
稠杂芳基取代的1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用
|
UA125592C2
(uk)
*
|
2017-03-16 |
2022-04-27 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ
|
EP3606962A4
(fr)
|
2017-04-04 |
2020-12-23 |
Corvus Pharmaceuticals, Inc. |
Méthodes de traitement des tumeurs à taux de cd73 élevés
|
ES2919474T3
(es)
|
2017-04-07 |
2022-07-26 |
Medshine Discovery Inc |
Derivado de [1,2,4]triazolo[1,5-c]pirimidina como inhibidor del receptor A2A
|
US11530273B2
(en)
|
2017-05-23 |
2022-12-20 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
WO2018237173A1
(fr)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
|
AU2018294557A1
(en)
|
2017-06-30 |
2020-01-02 |
Ryvu Therapeutics S.A. |
Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor
|
CN109535161B
(zh)
|
2017-09-22 |
2021-09-03 |
江苏恒瑞医药股份有限公司 |
***并嘧啶类衍生物、其制备方法及其在医药上的应用
|
MX2020004190A
(es)
|
2017-10-24 |
2020-08-03 |
Bayer Ag |
Amidas de imidazopiridina sustituidas y su uso.
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
BR112020015666A2
(pt)
|
2018-01-31 |
2021-02-23 |
Aptinyx Inc. |
moduladores de espiro-lactamas de receptores nmda e usos dos mesmos
|
MX2020008107A
(es)
|
2018-01-31 |
2020-09-25 |
Aptinyx Inc |
Moduladores del receptor nmda espiro-lactama y usos de los mismos.
|
IL276711B1
(en)
|
2018-02-17 |
2024-02-01 |
Astrazeneca Ab |
Arginase inhibitors and methods of using them
|
US20190292188A1
(en)
|
2018-02-27 |
2019-09-26 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
WO2019170131A1
(fr)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes
|
MX2020009366A
(es)
|
2018-03-09 |
2020-10-14 |
Phanes Therapeutics Inc |
Anticuerpos anti-cd73 y usos de los mismos.
|
AU2019231791B2
(en)
|
2018-03-09 |
2022-08-11 |
Agenus Inc. |
Anti-CD73 antibodies and methods of use thereof
|
AU2019245288C1
(en)
|
2018-03-30 |
2024-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
CA3096674A1
(fr)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Therapie combinee anticacner avec un antagoniste de cd73 et un antagoniste de l'axe pd-1/pd-l1
|
PE20211918A1
(es)
|
2018-05-11 |
2021-09-28 |
Incyte Corp |
Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1
|
US11168089B2
(en)
|
2018-05-18 |
2021-11-09 |
Incyte Corporation |
Fused pyrimidine derivatives as A2A / A2B inhibitors
|
CA3104467A1
(fr)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anticorps anti-pd-1 et leurs utilisations
|
AU2019297361A1
(en)
|
2018-07-05 |
2021-02-25 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
EP3820474A4
(fr)
|
2018-07-10 |
2022-03-23 |
Nikang Therapeutics, Inc. |
Composés se liant au récepteur de l'adénosine
|
AU2019322161A1
(en)
|
2018-08-13 |
2020-11-12 |
F. Hoffmann-La Roche Ag |
New heterocyclic compounds as monoacylglycerol lipase inhibitors
|
MX2021001433A
(es)
|
2018-08-13 |
2021-04-12 |
Hoffmann La Roche |
Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
|
GB201813678D0
(en)
|
2018-08-22 |
2018-10-03 |
Keybioscience Ag |
Acylated calcitonin mimetics
|
EP3840837B1
(fr)
|
2018-08-22 |
2024-03-20 |
Astrazeneca AB |
Inhibiteurs de l'arginase et leurs méthodes d'utilisation
|
AR116315A1
(es)
|
2018-09-12 |
2021-04-21 |
Dizal Jiangsu Pharmaceutical Co Ltd |
Compuestos de triazolo-pirimidina y usos de los mismos
|
JP2022503792A
(ja)
|
2018-09-26 |
2022-01-12 |
クラ オンコロジー,インク. |
メニン阻害剤を用いた血液悪性腫瘍の処置
|
WO2020073945A1
(fr)
|
2018-10-10 |
2020-04-16 |
江苏豪森药业集团有限公司 |
Inhibiteur de dérivé bicyclique, son procédé de préparation et son utilisation
|
UY38437A
(es)
|
2018-11-02 |
2020-05-29 |
Aicuris Gmbh & Co Kg |
Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
|
EP3883576A4
(fr)
|
2018-11-20 |
2022-06-22 |
Merck Sharp & Dohme Corp. |
Composés amino-triazolopyrimidine et amino-triazolopyrazine substitués utilisés en tant qu'antagonistes de récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
|
EP3889152A4
(fr)
|
2018-11-30 |
2022-09-07 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Dérivés hétéroaromatiques destinés à être utilisés comme régulateurs, leur procédé de préparation et leur utilisation
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
|
EP4010342A1
(fr)
|
2019-08-09 |
2022-06-15 |
Incyte Corporation |
Sels d'un inhibiteur de pd-1/pd-l1
|
JP2022545923A
(ja)
|
2019-08-26 |
2022-11-01 |
インサイト・コーポレイション |
A2a/a2b阻害剤としてのトリアゾロピリミジン
|
EP4037773A1
(fr)
|
2019-09-30 |
2022-08-10 |
Incyte Corporation |
Composés pyrido[3,2-d]pyrimidine en tant qu'immunomodulateurs
|
WO2021096849A1
(fr)
|
2019-11-11 |
2021-05-20 |
Incyte Corporation |
Formes salines et cristallines d'un inhibiteur de pd-1/pd-l1
|
IL294436A
(en)
|
2020-01-03 |
2022-09-01 |
Incyte Corp |
Anti-cd73 antibodies and their uses
|
US20210205311A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
|
AR124001A1
(es)
|
2020-11-06 |
2023-02-01 |
Incyte Corp |
Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Pd—1/pd—l1抑制劑之結晶形式
|
WO2022147092A1
(fr)
|
2020-12-29 |
2022-07-07 |
Incyte Corporation |
Polythérapie comprenant des inhibiteurs a2a/a2b, des inhibiteurs pd-1/pd-l1 et des anticorps anti-cd73
|